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Abstract
Background: CD36 is a multiligand receptor involved in various metabolic pathways, including cellular uptake
of long-chain fatty acids. Defect function or expression of CD36 can result in dyslipidemia or insulin resistance.
We have previously shown that CD36 expression is female-predominant in rat liver. In the present study,
hormonal and nutritional regulation of hepatic CD36 expression was examined in male and female rats. Since
alternative transcription start sites have been described in murine and human Cd36, we investigated whether
alternative CD36 transcripts are differentially regulated in rat liver during these conditions.
Results: Sequence information of the rat Cd36 5'-UTR was extended, showing that the gene structure of Cd36
in rat is similar to that previously described in mouse with at least two alternative first exons. The rat Cd36 exon
1a promoter was sequenced and found to be highly similar to murine and human Cd36. We show that alternative
first exon usage is involved in the female-predominant expression of CD36 in rat liver and during certain
hormonal states that induce CD36 mRNA abundance. Estrogen treatment or continuous infusion of growth
hormone (GH) in male rats induced CD36 expression preferentially through the exon 1a promoter. Old age was
associated with increased CD36 expression in male rats, albeit without any preferential first exon usage.
Intermittent GH treatment in old male rats reversed this effect. Mild starvation (12 hours without food) reduced
CD36 expression in female liver, whereas its expression was increased in skeletal muscle.
Conclusion: The results obtained in this study confirm and extend our previous observation that GH is an
important regulator of hepatic CD36, and depending on the mode of treatment (continuous or intermittent) the
gene might be either induced or repressed. We suggest that the effects of continuous GH secretion in females
(which is stimulatory) and intermittent GH secretion in males (which is inhibitory) explains the sex-different
expression of this gene. Furthermore, a female-specific repression of hepatic CD36 in response to food
deprivation was found, which was in contrast to a stimulatory effect in skeletal muscle. This demonstrates a tissue-
specific regulation of Cd36.
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Background
Fatty acid translocase (FAT or CD36) is a cell-surface glyc-
oprotein that functions as a multiligand receptor/trans-
porter involved in various diverse physiological processes
and disorders, including atherosclerosis, dyslipidemia,
insulin resistance and diabetes (reviewed in [1]). In
peripheral tissues active in fatty acid metabolism, such as
muscle and adipose tissues, CD36 facilitates the uptake of
long-chain fatty acids (LCFA) across the plasma mem-
brane. A null mutation of Cd36 reduces fatty acid (FA)
uptake rates and metabolism in these tissues [2], while its
over-expression results in the opposing effects [3,4].
Although CD36-deficient mice display reduced triacylg-
lycerol (TG) in muscle, lipid accumulation is increased in
the liver. The latter is probably due to increased plasma FA
concentrations and CD36-independent hepatic FA
uptake. As a consequence of these effects, insulin sensitiv-
ity is enhanced peripherally, while it appears impaired in
the liver [5]. Since muscle and adipose tissues shift to high
glucose utilization in CD36-deficiency, hypoglycemia and
hypoinsulinemia develop in the fasted state in CD36-defi-
cient mice [6]. Also, over-expression of CD36 in muscle
tissues is associated with hyperglycemia and hyperin-
sulinemia, as a result of enhanced FA utilisation and glu-
cose sparing. Taken together, expression-levels of CD36
affect lipid and glucose utilization and insulin sensitivity
in different tissues. Abnormal regulation of Cd36 expres-
sion might therefore contribute to the onset or severity of
several metabolic diseases.
CD36 abundance is regulated at different levels, including
gene expression, mRNA stability and protein expression
in a cell- and tissue-specific manner. Different physiolog-
ical conditions, where the nutritional and/or hormonal
status of the individual is affected, have been shown to
impact on CD36 levels in the plasma membrane. Regula-
tion at the level of mRNA expression in skeletal muscle
has been reported to include starvation, refeeding [7] and
exercise [8], but only a few studies report the molecular
mechanisms behind these effects. Although PPARα,
PPARγ [9,10], PXR [11], NR4A (Nu77) [12] and Foxa2
(HNF3β) [13] have been shown to affect CD36 expres-
sion, no direct interaction of these transcription factors in
the  Cd36  promoter have been described. Furthermore,
recent analyses of the Cd36 gene has revealed a compli-
cated promoter structure with alternative transcription
start sites [14,15]. Alternative promoter usage has been
shown to contribute to tissue-specific regulation of CD36
expression in both mice and humans [14,15]. Although
the alternative promoters are mapped in the human and
murine Cd36 genes, less information is available for the
rat gene.
Hepatic CD36 has not been considered physiologically
important, due to low level of expression in the liver and
the fact that hepatic lipid uptake is independent of CD36.
Perhaps as a consequence of this, little is known about
hepatic Cd36 gene regulation. However, we have recently
shown that CD36 expression is female-predominant in rat
liver [16]. It was also shown that the female pattern of
growth hormone (GH) secretion induces CD36 mRNA
levels in male liver, suggesting that there might be condi-
tions where increased or decreased activities of hepatic
CD36 is needed and that these conditions might be
slightly different in male and female livers. The aim with
the present study was to extend our knowledge about reg-
ulatory mechanisms behind hepatic CD36 expression.
Since alternative CD36 transcripts have been described in
mouse and human tissues, we investigated whether alter-
native transcription start sites might be involved in differ-
entially regulating CD36 mRNA abundance in rat liver in
different hormonal and nutritional states.
Results and discussion
Comparison between mouse and rat Cd36 gene structures
The mouse Cd36  gene has at least three characterized
untranslated first exons and corresponding promoters,
resulting in three major alternative transcripts [17]. Simi-
larly, the human Cd36 gene can be expressed from five
alternative first exons [14]. When the first exon of rat Cd36
([GenBank:NM_0031561]) is mapped to the genome
browser it is equivalent to exon 2 in the human and
mouse genes. Gene structures and exon distances are oth-
erwise similar between mouse and rat. Since the rat
genomic sequence is incomplete upstream of exon 2
(when extrapolated to the mouse and human gene struc-
tures), we looked for rat exon 1a and 1b in the UCSC
genome database. A few ESTs showed high sequence
homology to corresponding mouse exon 1b. However,
the estimated location of rat exon 1a fell within regions
where sequence information is unavailable.
To determine whether the rat Cd36 5'-untranslated region
(UTR) is similar to that of the mouse, primers were
designed from the common sequences between mouse
and rat; for exon 1a according to [GenBank:BC010262]
(mouse) and [GenBank:AB005743] (rat), and for exon 1b
according to [GenBank:NM_007643] (mouse) and [Gen-
Bank:AW919183] (rat). PCR products derived from male
or female rat hepatic cDNA, corresponding to regions
from either exon 1a to exon 3 (1a-3) or from exon 1b to
exon 3 (1b-3), were generated and sequenced. The ampli-
fied products appeared as single bands, as examined by
gel electrophoresis, with the corresponding estimated
sizes of 250 bp for 1a-3 and 150 bp for 1b-3. Upon
sequencing, it was apparent that these products had differ-
ent first exon sequences but identical exon 2 and 3
sequences ([GenBank:EF116601] and [Gen-
Bank:EF116602]). This finding suggests that the use of
exon 1a and exon 1b is mutually exclusive in rat liver (Fig-BMC Molecular Biology 2007, 8:60 http://www.biomedcentral.com/1471-2199/8/60
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ure 1). Furthermore, high similarity scores between
mouse and rat exon 1a-3 (92%) and 1b-3 (94%)
sequences, suggest that the sequenced PCR products orig-
inating from rat liver are homologous to the correspond-
ing mouse CD36 transcripts. Aligning human and rodent
exon 1a and 1b sequences revealed low similarities.
Since sequence information for rat Cd36 exon 1a and its
promoter is limited, this promoter was cloned from rat
liver DNA. Primers were designed corresponding to highly
conserved genomic regions within the human and mouse
exon 1a promoter. The amplified product was estimated
to be 450 bp long with a sequence similar to that of the
mouse 1a promoter region, as described by Sato et al. [17].
This sequence [GenBank:EF116603] was also identical to
part of a cloned rat Cd36 promoter [GenBank:AF317787],
not mapped in genome databases (Figure 2A). Alignment
of these rodent promoter sequences and the human exon
1a promoter revealed 70% similarity in the region of -200
bp, whereas the corresponding promoter regions of exon
1b were slightly less similar (53%) (Figure 2B). This sug-
gests that the regulatory function of these promoters
might be evolutionarily conserved.
Tissue-specific expression patterns of alternative first
exons of Cd36 have been described in mouse [15] and
human [14], suggesting that the alternative first exons of
the gene are regulated individually. According to Sato et
al., exon 1a is more expressed in liver than muscle,
whereas the opposite is shown for exon 1b [15]. Compar-
ing expression levels in human tissues active in FA metab-
olism, exon 1a is highest expressed in adipose tissue,
followed by heart, skeletal muscle and liver, with a ratio
of approximately 100 between adipose tissue and liver
[14]. Exon 1b showed the same relative expression levels,
but only 10 fold differences between fat and liver [14].
Whether males and females have different tissue-specific
patterns of alternative first exons was not investigated in
the studies referred to.
Sex different expression of CD36 transcripts in mouse and 
rat liver
We next wanted to determine a possible role for alterna-
tive promoter usage in the previously described sex-differ-
ent expression of CD36 in rat liver. Expression levels of
exon 1a and 1b were thus analyzed in male and female liv-
ers from rats and mice by real-time PCR and compared to
exon 3–4, representing the protein coding region. As dem-
onstrated in Figure 3, the exon 1a-3 transcript was signifi-
cantly higher expressed in females as compared to males,
in both species. Although similar results were obtained for
exon 1b-3 and the coding region (exon 3–4), the sex-dif-
ference was most pronounced for exon 1a-3. A species dif-
ference in the degree of sex-dependence was observed for
all transcripts measured, with larger differences in rats.
Compared to males, female rats had 4.4 times higher
expression of the exon 3–4 transcript in liver, whereas the
difference was only 1.5 times in mice. Similarly, female
rats had 6-fold higher levels of exon 1a-3 compared to
males. In the mouse, female expression was only 2.3-fold
higher compared to males.
Hormonal regulation of hepatic CD36 expression
Many hepatic sex-differences in gene expression can be
explained by sex-different levels of different hormones.
Male rats exposed to estrogen display a "feminized" pat-
tern of hepatic gene expression [18]. GH also exerts femi-
nizing effects, but only if delivered in a continuous
fashion that mimics the endogenous female secretory pat-
tern of GH (GHc). A male pattern of hepatic gene expres-
sion can instead be induced by intermittent
administration of GH (GHi) [19]. This can be explained
by the fact that plasma GH profiles are sexually dimorphic
in rodents. Male rats secrete GH in an episodic rhythm in
which interpulse periods contain no detectable levels of
the hormone. GH secretion in the female rat is also pulsa-
tile, but can be characterized as "continuous" since hor-
mone levels are always present in the circulation. Old age,
which is associated with reduced pulse amplitude but
unchanged trough GH values in male rats, has also been
shown to "feminize" hepatic gene expression [20,21]. In
mice, although the pulse frequencies are greater in
females, GH levels in peaks and interpeaks are the same
between males and females [22]. This might explain why
some sex-dependent and GH regulated genes (such as
CD36) are more sex-differentiated in rats as compared to
mice.
In attempts to find putative hormonal factors behind the
female-predominant expression of CD36 in rat liver, the
hormonal states described above were investigated regard-
ing hepatic CD36 mRNA expression. Expression levels of
exons 1a-3, 1b-3, and 3–4 were compared between "fem-
inized" and untreated (young) adult males. As demon-
strated in Figure 4A, all transcripts were significantly
increased in "feminized" males, except for exon 1b-3 in
17α-ethinylestradiol (EE) treated males. The feminizing
effect was highest for exon 1a-3, suggesting that that EE
and GHc treatment might induce CD36 expression prefer-
entially through the exon 1a promoter whereas the
changes associated with old age might have another
mechanism of action.
When old male rats were treated by episodic administra-
tion of GH (GHi), which mimics the endogenous secre-
tory pattern of GH in young adult male rats, Cd36 gene
expression was repressed and restored to the same level as
in young adult males (Figure 4B). However, exon specific
repression by GHi treatment was not observed. This is in
line with the finding that old age induced exons 1a-3, 1b-BMC Molecular Biology 2007, 8:60 http://www.biomedcentral.com/1471-2199/8/60
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The sequence of Cd36 Figure 1
The sequence of Cd36. Obtained sequences ([GenBank:EF116601] and [GenBank:EF116602]) were aligned to known 
sequences of Cd36 exon 1a, 1b, 2 and 3 using the multiple alignment program ClustalW version 1.83, available on the EBI web-
site. The reverse strand is shown in mouse sequences. Base numbers specific to the individual sequences are presented. The 
transcription start site in exon 3 is bold and highlighted. Asterisks indicate bases which are identical among all three species.
Exon 1a 
Rat-1a-EF116601        -----------------------------------------TGC-AACT- 7 
Human-1a-CB958830      GGAAAACACAACCAGAGTCTTCGGTGTTAATTCCCTGGTCTTCCCAACTA 50 
Mouse-1a-BC010262      ---------------------------------TGTAACCTTGC-AACT- 15 
Rat-1a-AB005743        ------------CTTTGAAGAGATCAGTGACTCTGTAACCTTGC-AACT- 36 
                                                                * * ****
Rat-1a-EF116601        GCATTTTGATGGTTCCTTTAAACTCGTGGACTTGTACTCTCTCCTCGGAT 57 
Human-1a-CB958830      GCATTCTGAAAGTGCATTAACATTTGTGGCCTTGTGCTCTTTCATCGGAC 100 
Mouse-1a-BC010262      GCATTTTGATGGTTCCTTTAAACTTGTGGCCTTGCACTCTCTCATCGGAC 65 
Rat-1a-AB005743        GCATTTTGATGGTTCCTTTAAACTCGCGGACTTGTACTCTCTCCTCGGAT 86 
                       ***** ***  ** * ** * * * * ** ****  **** ** *****
Rat-1a-EF116601        GGCTAGCTGATTACTTCTGTGTA 80 
Human-1a-CB958830      TTCTAA---------------TG 108 
Mouse-1a-BC010262      TTCTAGCTGATTACTTCTGTGTA 88 
Rat-1a-AB005743        GGCTAGCTGATTACTTCTGTGTA 109 
                         ***                *
Exon 1b
Rat-1b-EF116602        -------------------------------------------------- 0 
Human-1b-NM_001001548  GAGGACTGCAGTGTAGGACTTTCCTGCAGAATACCATTTGATCCTATTAA 50 
Mouse-1b-NM_007643     ------------------------GACTGAGGACTTTTTCTTCTTCACAG 26 
Rat-1b-AW919183        -----------------------------------GTTTCTTCTTCACAG 15 
Rat-1b-EF116602        ------------------GGAGCAACTGGTGAATGG---TTTCCTAGCT- 28 
Human-1b-NM_001001548  GAATTGTCC-AAATGT-TGGAGCATTTGATTGAAAAATCCTTCTTAGCCA 98 
Mouse-1b-NM_007643     CTGCCTTCTGAAATGTGTGGAGCAACTGGTGGATGG---TTTCCTAGCC- 72 
Rat-1b-AW919183        CCGCCTTCTGAAATGTGTGGAGCAACTGGTGAATGG---TTTCCTAGCT- 61 
                                         ******  ** *  *       *** ****
Rat-1b-EF116602        TTTCAAAG 36 
Human-1b-NM_001001548  TTTTAAAG 106 
Mouse-1b-NM_007643     TTTCAAAG 80 
Rat-1b-AW919183        TTTCAAAG 69 
                       *** ****
Exon 2 
Rat-1a-EF116601        GTAGCTTACAAATGATTCGAAGTGTTGAAACTTTCTGAGTCTCAATGAAC 130 
Rat-1b-EF116602        GTAGCTTACAAATGATTCGAAGTGTTGAAACTTTCTGAGTCTCAATGAAC 86 
Human-NM_001001548     ATAGCTTTCCAATGATTAGACGAATTGATTCTTTCTGTGACTCATCAGTT 156 
Mouse-NM_007643        GTAGTTTACAAATGATTTGAAGTGCTGATCCTTTCAGAGTCTCAACAGAT 130 
Rat-NM_0031561         GTAGCTTACAAATGATTCGAAGTGTTGAAACTTTCTGAGTCTCAATGAAC 97 
                        *** ** * ******* ** *   ***  ***** * * ****
Rat-1a-EF116601        TATTTCTCACACAACTCAGATACTGCTGTTCATGCATGAATTAG 174 
Rat-1b-EF116602        TATTTCTCACACAACTCAGATACTGCTGTTCATGCATGAATTAG 130 
Human-NM_001001548     CATTTCCTGTAAAATTCATGTCTTGCTGTTGATTTGTGAATAA- 199 
Mouse-NM_007643        TATTTCTTAAACAGCTCATACATTGCTGTTTATGCATGAATTAG 174 
Rat-NM_0031561         TATTTCTCACACAACTCAGATACTGCTGTTCATGCATGAATTAG 141 
                        *****    * *  ***    ******* **   ***** *
Exon 3 
Rat-1a-EF116601        T-GAACCAG-CCACA-AGAATG---------------------------- 193 
Rat-1b-EF116602        T-GAACCAG-CCACAAGAATTG---------------------------- 150 
Human-NM_001001548     --GAACCAGAGCTTGTAGAAACCACTTTAATCATATCCAGGAGTTTGCAA 247 
Mouse-NM_007643        TAGAACCGGGCCACGTAGAAAACACTGTGATTGTACCTGGGAGTTGGCGA 224 
Rat-NM_0031561         TTGAACCAGGCCACATAGAAAGCATTGTAATTGTACCTGTGAGTTGGCAA 191 
                         ***** *  *      *
Rat-1a-EF116601        -------------------------------------------------- 
Rat-1b-EF116602        -------------------------------------------------- 
Human-NM00100548       GAAA-CAGGTGCTTAACACTAATTCACCTCCTGAACAAGAAAAATGGGCT 296 
Mouse-NM_007643        GAAAACCAGTGCTCTCCCTTGATTCTGCTGCACGAGGAG---AATGGGCT 271 
Rat-NM_0031561         GAAG-CAAGTGCTCTTCCTTGATTCTGCTGCACGAGGAGGAGAATGGGCT 240 
ATG
3
1
a
1
b
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The sequence of the Cd36 promoter Figure 2
The sequence of the Cd36 promoter. A. Promoter sequences were extracted from UCSC genome browser upstream of 
Cd36 exon 1a from mouse [GenBank:BC010262] and human [GenBank:CB958830] and aligned to the previously described rat 
promoter [GenBank:AF317787] and the sequence obtained in this study [GenBank:EF116603]. Base numbers for [Gen-
Bank:AF317787] and [GenBank:EF116603] are specific to the respective sequences. For others, transcription start site of exon 
1a (+1) is referred to as the first base of the sequence. The reverse strand is shown in mouse sequences. Corresponding exon 
sequences for the different species are shadowed. In rat, the exon 1a region was determined by aligning the promoter 
sequence with [GenBank:AB005743], where the first three bases were excluded due to inconsistency. B. Summary of murine 
Cd36 gene structure which consists of 15 exons. Exons 1a, 1b and 2, first part of exon 3, and exon 15 are untranslated regions 
(UTR). The sequences of exon 1a and its promoter as well as exon 1b were identified in this study (shaded area). The use of 
these two alternative first exons is mutually exclusive. The degree of sequence conservation among human, mouse and rat in 
the promoters (200 bp upstream) of exon 1a and exon 1b are presented. Approximate distances between exon 2 and the 
alternative first exons in mouse are also indicated. Arrows represent the position of exon-specific primers for real-time PCR 
analysis.
A
Exon 1a promoter 
Rat-EF116603    --------------------------TCCTTTCTTCCTTTCTTTCTTCCT-------CTT 27 
Human           GTTTCTGTGTGCTTTTAGACATCACAGAGTAATTGTTTCTTTTTTTAAAGGAAGGAACCA -177 
Mouse           CTTTCCTT----------TCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTC-------CTT -200 
Rat-AF317787    CTTTCTTTCTTCCTTTCTTCCTTTCTTCCTTTCTTCCTTTCTTTCTTCCT-------CTT 2026 
                                                 *   *   ***             *
Rat-EF116603    TCTTAAAGAGCAATTCACGTTTAAGCTGGACAGGTTAACAAAAGCTGGATGCCAGGCTTA 87 
Human           GGGTGAAGAGCAGCTCATTTTTAAGCTGGAGAGGTTAACAAACACTGGCTGCAAGATTTA -117 
Mouse           TCCTAAGGAGCAGTTCATTTTTAAGCTGGGTAGGTTAGCAAATGCTGGATGCCAGGTTTA -140 
Rat-AF317787    TCTTAAAGAGCAATTCACGTTTAAGCTGGACAGGTTAACAAAAGCTGGATGCCAGGCTTA 2086 
                   * * *****  ***  **********  ****** ****  **** *** **  *** 
Rat-EF116603    CTTTGGTTTATAAGCTTCACTGCTGCACTGGAGCGTCAATCAAAGTTCCACAGCCACTCT 147 
Human           CTTTGGTTTAGGAATACCACTGTCTCACAGGAGTGTCAATCAAAATTCCACAGCCATTCT -57
Mouse           CTTTGGTTCAGAAACTTCACTGCTGCACTAGAGTGTCAATCAAAATTCCACAGCCATTCT -80 
Rat-AF317787    CTTTGGTTTATAAGCTTCACTGCTGCACTGGAGCGTCAATCAAAGTTCCACAGCCACTCT 2146 
                ******** *  *    *****   ***  *** ********** *********** *** 
Rat-EF116603    TGGATACTTGGAGGTGGGGCTAAGTGGTGAGCAGCAGTGATTTGAC-------TTGGGGC 200 
Human           TCGACACTAGGAGGTGGGACTGACTGATGTACAGCAGTGATTTGACCCAGCACTTGGGGC +3 
Mouse           AGGACACTTGGAGGTGGGGCTAAGTGGTGAGCAGCAGTGATTTGAC-------TTGTGGC +573 
Rat-AF317787    TGGATACTTGGAGGTGGGGCTAAGTGGTGAGCAGCAGTGATTTGAC-------TTGGGGC 2199 
                  ** *** ********* ** * ** **  ***************       *** *** 
Rat-EF116603    AAAAAAGGCTGGAGAGATCAGTG---ACTCTGTAACCTTGC-AACT-NC----------- 244 
Human           AAACACAACCAGAGTCTTCGGTGTTAATTCCCTGGTCTTCCCAACTAGCATTCTGAAAGT +63 
Mouse           AAACAGGGCTGGAGATATCAGGG---ACTCTGTAACCTTGC-AACT-GCATTTTGATGGT +28 
Rat-AF317787    AAAAAAGGCTGGAGAGATCAGTG---ACTCTGTAACCTTGC-AACT-GCATA-------- 2246 
                *** *   *  ***   ** * *   * **  *   *** * ****  *
BBMC Molecular Biology 2007, 8:60 http://www.biomedcentral.com/1471-2199/8/60
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3, and 3–4 to similar extent (Figure 4A and 4B). This sug-
gests that the low level of Cd36  expression in (young
adult) male rats might be due to the pulsatile secretion of
GH in males. When this pattern of GH secretion becomes
less pulsatile (regarding the pulse amplitude) as the male
rats get older, this inhibition is released and CD36 mRNA
levels increase. We speculate that regulatory DNA
sequences mediating the inhibitory action of pulsatile GH
are present in both exon 1a and 1b promoters, whereas
those important for the stimulatory effect of continuous
GH are specific for exon 1a.
Since our studies were performed on whole animals it is
impossible to determine whether the hormonal effects on
CD36 expression are due to direct effects on the liver or
through secondary changes. The dose of EE used in this
study has been shown to "feminize" the male rat liver
[23]. The relatively weak effect of this treatment might be
due to an indirect action on the liver, with estrogen acting
on the pituitary by altering the pattern of GH secretion.
Estrogen treatment of male rats is known to "feminize"
the secretory pattern of GH into a more continuous mode
[24]. However, the greater effect obtained by GHc treat-
ment compared to estrogen, could also be explained by
other indirect effects of GH treatment. GH is for instance
well-known to stimulate adipose lipolysis, leading to
increased levels of circulating free fatty acids [25], which
might reprogram hepatic gene expression through various
lipid-modulated transcription factors.
Nutritional regulation of CD36 expression
The nutritional status of the individual has been shown to
affect CD36 expression in skeletal muscle, including star-
vation-mediated up-regulation [7]. Both starvation and
increased secretion of GH will lead to activation of lipoly-
sis in the adipose tissue, increased levels of circulating
fatty acids, as well as increased expression of CD36 in
muscle (starvation) or liver (GH). To determine whether
the level of CD36 expression and thus ability to import
LCFA is coordinated between muscle and liver, we com-
pared these tissues regarding the different CD36 tran-
scripts in animals deprived of food for either 4 or 12
hours. Animals that have been without food for 12 hours
(fasting) should have an increased lipolysis in compari-
son to 4 hours. As demonstrated in Figure 5A, 12 h of food
deprivation led to significantly reduced CD36 mRNA
expression in livers from females, without any differences
in alternative exon 1 transcripts. No effect was observed in
male rats. As a consequence, the sex difference in CD36
expression was greatly reduced in the fasted rats. In con-
trast, the expression of CD36 in skeletal muscle was
increased in both males and females (Figure 5B). This
stimulatory effect of food withdrawal was highest for exon
1a-3, suggesting that fasting might induce CD36 expres-
sion preferentially through the exon 1a promoter. These
observations confirms previous reports on Cd36 regula-
tion in skeletal muscle [7], and shows that CD36 expres-
sion is differently regulated in muscle and liver. As
demonstrated in Figure 5C, the starvation-mediated
down-regulation of CD36 in female livers could also be
observed at the protein level, indicating that animals in
this nutritional state might prioritize muscular uptake of
LCFA at the expense of hepatic.
In silico promoter analysis of the rat Cd36 promoter
As described above, the gene structure of Cd36 in rat is
similar to that described in mouse, with at least two alter-
native first exons (exon 1a and 1b). We observe a female-
predominant expression of the transcripts starting with
both exon 1a and exon 1b, but the sex-specific expression
difference is greater for the transcripts starting with exon
1a. The exon 1a-specific up-regulation of CD36 is even
more pronounced after GHc-induction in male rat liver.
The effects of old age and starvation in liver, on the other
hand, appeared to be independent of alternative first exon
usage. We therefore wanted to identify putative transcrip-
tion factor binding sites (TFBS) within the exon 1a and 1b
promoters which might be able to explain the observed
Effects of sex on hepatic CD36 mRNA expression in mice  and rats Figure 3
Effects of sex on hepatic CD36 mRNA expression in 
mice and rats. mRNA expression of CD36 was quantified 
by real-time PCR in livers from male or female mice (A) and 
rats (B). Exon-specific primers were used to measure the 
mRNA abundance of specific regions of the transcript, which 
were normalized to the mRNA level of GAPDH in mouse 
and that of RPLP0 in rat samples. Data are presented in rela-
tion to the expression level of the same transcript in male 
counterparts. The obtained data were analyzed using Stu-
dent's T-test and bars represent the mean ± S.E. Asterisks 
indicate significant sex differences (p < 0.05).
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Effects of different hormonal treatments on hepatic CD36 mRNA expression in male rats Figure 4
Effects of different hormonal treatments on hepatic CD36 mRNA expression in male rats. mRNA expression of 
CD36 exon 1a-3 (A), exon 1b-3 (B) and exon 3–4 (C) was quantified by real-time PCR in livers from males, females, males 
treated with continuous infusion of GH (GHc), males treated with injections of estradiol, old males or old males treated with 
twice daily injections of GH (GHi). Exon-specific primers were used to measure the mRNA abundance of specific regions of 
the transcript, which were normalized to RPLP0 mRNA level. Data are presented in relation to the expression level of the 
same transcript in male rats. The obtained data were analyzed using Student's T-test and bars represent the mean ± S.E. Aster-
isks indicate statistically significant differences versus male (*) whereas circles (¤) indicate significant effects of GHi in old males 
(p < 0.05).
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differences and similarities regarding first exon usage in
rat liver.
We used the Match™ program, in which position specific
weight matrix (PWM) models are used to predict TFBS,
and the Consite program to identify evolutionary con-
served sequences between rat, mouse and human in the
upstream regions of the alternative first exons of CD36.
The sequences from -600 to +50 base pairs relative to the
transcription start sites of the two exons were found to be
highly conserved between species (see additional file), so
we focused the in silico analysis on these regions. PWM
models of TFBS have been shown to predict sites that are
functional in vitro [26] but it is also well known that the
method results in a high number of predictions that are
non-functional in vivo [27]. In order to make as relevant
predictions as possible, we limited our analysis to availa-
ble PWMs for transcription factors known to be expressed
in the liver (GATA3, NF1 and PBX1) and transcription fac-
tors that are known from the literature to be sex-depend-
ent or controlled by GH (AP-1, C/EBPβ, HNF3β, SOX9,
SRY and STAT5, reviewed by Waxman and O'Connor
2006 [28]). Predicted binding sites for the available tran-
scription factors are shown in Figures 6A (exon 1a) and 6B
(exon 1b). Most of the putative TFBS were conserved
between rat and mouse and some could also be predicted
in the human promoters. Please refer to additional files
for sequences, positions and other information related to
these putative TFBS. Some TFBS were found to be com-
mon between the two promoters, such as those for
HNF3β, whereas others were promoter-specific. The two
putative binding sites for HNF3β were both found to be
conserved between rat and mouse and might be of special
interest since constitutively active HNF3β was previously
shown to increase hepatic CD36 expression [13]. Further-
more, the level of HNF3β in rat liver has been shown to be
GH-dependent [29] and to induce the expression of the
female-specific Cyp2c12 transcript in rat liver [30]. Need-
less to say, this does not imply that CD36 expression is
regulated in the same manner as Cyp2c12.
Since exon 1a containing transcripts were shown to
increase more in response to GHc, there might be inhibi-
tory factors operating within the exon 1b promoter.
STAT5b is a candidate repressor as it is activated in male
rat liver in direct response to each incoming plasma GH
pulse and is partially down-regulated by a continuous,
female-like pattern of GH-stimulation [31,32]. STAT5b
has been proposed to collaborate with the HNFs to regu-
late the sex-dependent hepatic expression of cyp-genes
[30,33]. No putative STAT5b binding sites were however
revealed within either promoter. Binding sites for the
male-specific transcription factors Sry (sex-determining
region on the Y chromosome) and SOX9 (Sry-related
HMG box-9) were identified within the exon 1b pro-
moter. Overexpression of the SRY-like protein IRE-ABP
(SOX4) has been shown to inhibit the stimulatory effect
of C/EBPα on Cyp2c12 expression in primary hepatocytes
[34]. Purely speculative, similar mechanism might oper-
ate within the exon 1b promoter, which could explain the
differences in the amount of up-regulation of exon 1a and
exon 1b in GHc treated male rats.
As mentioned above, PWMs have been shown to produce
a lot of false positive binding site predictions. Potential
sites must therefore be validated experimentally before
any conclusions can be drawn about which transcription
factors mediate the up- or down-regulation of the alterna-
tive first exons of CD36 observed in this study. Neverthe-
less, these predictions are based on the currently available
tools for in silico predictions of regulatory elements, and
can be considered a first guess and a guide to which sites
to prioritize for further in vitro and in vivo studies.
Conclusion
The aim of this study was to improve our knowledge
about regulatory mechanisms behind hepatic Cd36
expression. We have extended the sequence information
of the rat Cd36 5'-UTR and shown that the gene structure
of Cd36 in rat is similar to that described in mouse, which
contains at least two alternative first exons (exon 1a and
1b). The rat Cd36 exon 1a promoter was sequenced and
shown to be highly similar to human and murine Cd36. A
greater sex-specific expression difference was observed for
the transcripts starting with exon 1a in rat liver. Further-
more, estrogen or GHc treatment of male rats induced
CD36 expression preferentially through the exon 1a pro-
moter. Old age was also associated with increased CD36
expression in male rats, albeit without any preferential
first exon usage. GHi treatment in old male rats reversed
(reduced) this effect. Similarly, the two different exon 1
containing transcripts were equally well reduced in
response to starvation in female rats. The results obtained
in this study confirm and extend our previous observation
that GH is an important regulator of hepatic CD36, and
depending on the mode of treatment (continuous or
intermittent) the gene might be either induced or
repressed. We therefore suggest that the effects of contin-
uous GH secretion in females (which is stimulatory) and
intermittent GH secretion in males (which is inhibitory)
explains the sex-different expression of this gene.
Methods
Animals and treatments
Male (n = 5) and female (n = 6) Sprague-Dawley rats (ten
weeks of age) and C57BL/6 mice (six of each sex) were
maintained under standardized conditions. Food
restricted animals, in groups of four, were either without
chow from 11 PM to 11 AM (12 h food withdrawal), or
from 7 AM to 11 AM (4 h food withdrawal). Where indi-BMC Molecular Biology 2007, 8:60 http://www.biomedcentral.com/1471-2199/8/60
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Effects of food deprivation on CD36 expression in liver or skeletal muscle from male and female rats Figure 5
Effects of food deprivation on CD36 expression in liver or skeletal muscle from male and female rats. mRNA 
expression of hepatic (A) or skeletal muscle (B) CD36 was quantified by real-time PCR in male and female rats after 4 or 12 
hours of food deprivation (FD). Exon-specific primers were used to measure the mRNA abundance of specific regions of the 
transcript, which were normalized to the mRNA level of RPLP0 in liver and that of ARBP in muscle. Data are presented in rela-
tion to the expression level of the same transcript in male rats after 4 hours of FD. The obtained data were analyzed using Stu-
dent's T-test and bars represent the mean ± S.E. Asterisks (*) indicate significant sex differences whereas circles (¤) indicate 
significant effects of starvation (p < 0.05) Protein expression of hepatic CD36 in male and female rats after 4 or 12 hours of FD 
using immunoblot (C).
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cated, five male rats (ten weeks of age) were treated with
bovine GH (a kind gift from Pharmacia and Upjohn AB)
by continuous infusion from osmotic minipumps, as
described in [16]. Old (18 months of age) male rats were
injected twice daily with GH (n = 5) or vehicle (n = 4), as
described in[21]. Six young animals (ten weeks of age)
were injected subcutaneously once daily with 17α-ethi-
nylestradiol (EE) (Sigma, E-4876), as described previously
[23]. Control animals (n = 5) received equivalent
amounts of the vehicle alone. After one week of treat-
ments, animals were anesthetized and sacrificed. Tissues
were removed, immediately frozen in liquid nitrogen, and
stored at -80°C until further analysis. All animal experi-
ments were approved by the institutional animal care and
use committee.
RNA isolation, cDNA synthesis and real-time PCR
Total RNA was extracted from frozen livers or skeletal
muscle with TRIzol®Reagent (Invitrogen Life Technolo-
gies). Before reverse transcription, DNA was removed by
RQ1 RNase-free DNAse (Promega). From 5 μg of total
RNA, the first strand cDNA was made using iScript™ cDNA
synthesis kit (Bio-Rad Laboratories, CA). Exon-specific
primers were designed by the Primer3 program [35] and
synthesized by Thermo, as summarized in Table 1. The
setup of primers is presented in Figure 2B. The following
reference genes were used; ribosomal protein large P0
(Rplp0) for rat liver; acidic ribosomal phosphoprotein P0
(Arbp) for rat muscle; glyceraldehyde-3-phosphate dehy-
drogenase (Gapdh) for mouse liver.
Real-time PCR was performed from first strand cDNA
with iQ™ SYBR® Green Supermix (Bio-Rad Laboratories,
CA) in DNA Engine Opticon™2 System (MJ Research,
CA). Relative standard curves were constructed using
serial dilutions of pooled cDNA representing all individ-
ual hepatic RNA samples used in this study. The specific
transcript levels were determined using Opticon Monitor
3, normalized with the level of the corresponding refer-
ence gene in each sample, and the obtained data were ana-
lyzed using Student's T-test. We observed a certain
variation in the absolute mRNA levels. At the present we
suspect that the nutritional state of the individual animals
might contribute to this.
Sequencing and sequence alignment
Primers used to clone the promoter of exon 1a are left
primers in the genomic region, 5'-GAGCAGTTCATTTT-
TAAGCTG-3' and 5'-AAGGGGATTGCTGTGA-3', and right
primer in exon 1a 5'-ACCATCAAAATGCAGTTG-3'. For
exon 1a, 1b to exon 3, primers used are the same as for the
real-time PCR. Exon 1a, 1b and the promoter of exon 1a
were amplified by PCR using standard conditions and
sequenced in duplicates using BigDye™ reagents (Amer-
sham Biosciences) on an ABI sequencer. Multiple
sequence alignment was then performed by the program
Clustal W version 1.83 [36].
In silico promoter analysis
Orthologous promoter sequences from human, mouse
and rat Cd36  were extracted from the UCSC genome
Putative transcription factor binding sites within the alterna- tive Cd36 1a and 1b promoters Figure 6
Putative transcription factor binding sites within the 
alternative Cd36 1a and 1b promoters. Selected liver- 
or sex-specific putative transcription factor binding sites 
(TFBS) were predicted in the most conserved regions (600 
bp upstream to 50 bp downstream of TSS) of rat Cd36 1a (A) 
and 1b (B) promoters, using the Match™ program (available 
from the TRANSFAC® website). All TFBS indicated in the fig-
ure have more than 90% similarity score in both core match 
and matrix match. The degree of sequence conservation 
between rat and mouse sequences within these two pro-
moter regions is indicated in the figure. Putative TFBS in blue 
and bold are conserved between mouse and rat, whereas 
those in red, bold and italic are conserved among human, 
mouse and rat. See additional file for the exact positions of all 
putative TFBS, the corresponding scores, matrix identifiers 
and sequences.BMC Molecular Biology 2007, 8:60 http://www.biomedcentral.com/1471-2199/8/60
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browser and [GenBank:AF317787]. Pairwise alignment
with the ORCA algorithm was used to identify conserved
regions by CONSITE [37]. Putative transcription factor
binding sites (TFBS) were predicted in the sequences for
promoter 1a and 1b by Match™ program public version
1.0 [38]. The program uses a library of mononucleotide
weight matrices from TRANSFAC® 6.0. We limited our
analysis to matrices corresponding to transcription factors
known to be expressed in liver (GATA3, NF1 and PBX1) or
known to be sex- or GH dependent (AP-1, C/EBPβ,
HNF3β, SOX9, SRY and STAT5). The PWM for STAT5 was
found in a publication by Ehret et al. [39] and analyzed
separately. We reported TFBS predictions that gave a rela-
tive score of at least 90% of the best possible match
between the matrix model and the DNA sequence. See
additional files for more information.
Immunoblotting
Whole liver cell lysates were obtained by homogenizing
100 mg of liver in 1 ml RIPA buffer (50 mM Tris-HCl, pH
7.4, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, 1 mM
PMSF, 1 mM Na3VO4, 10 mM NaF, 1 μg/ml of aprotinin,
leupeptin, and pepstatin), using a polytrone PT-2000
(Kinematica AG), followed by 20 minutes of centrifuga-
tion (12 000 g). The resulting supernatants were collected
and proteins resolved by SDS-PAGE on PVDF membrane.
The membranes were blocked for 1 h in Tris-buffered
saline (TBS; 10 mM Tris pH 8.0, 150 mM NaCl) contain-
ing 0.1% (v/v) Tween-20 and 5% (w/v) milkpowder (TBS-
MILK), incubated overnight with monoclonal anti-CD36
antibodies (anti murine CD36, Cascade Biosciences)
diluted 1:2500 in TBS-MILK, washed and incubated with
the secondary antibody (1:10000) (goat anti-mouse IgG,
Santa Cruz, CA). After additional washing steps antibody
binding was visualized using an ECL detection system
(Pierce Biotechnology, Inc).
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